Emerging Paradigms in Delivery of Therapeutic Agents for the Treatment of Glioblastoma

Rajeev Sharma is an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Madhya Pradesh, Gwalior, India. He earned his B.Pharm, M.Pharm, and Ph.D. in Pharmaceutical Sciences from Dr. H. S. Gour Central University, Sagar, India. Dr. Sharma has approximately 13 years of experience in both teaching and industry. He has served as a Junior Research Fellow under AICTE, an ICMR-SRF, and a CSIR-RA Fellow during his research career, and has worked as an Assistant Professor in academia and as a Senior Formulation Development Scientist in the R&D industry. Dr. Sharma has edited two international and two national books and has authored over 30 publications and 21 book chapters in international reference books. His work focuses on recent concepts in immunology, nanobiotechnology, novel drug delivery systems, and targeted and controlled drug delivery of bioactives for the treatment of diseases such as cancer and diabetes. He is a life member of the Association of Pharmaceutical Teachers of India (APTI). Dr. Sharma's work has been cited approximately 1,200 times, and he has an h-index of 17. The cumulative impact factor of his published papers is around 120, according to SCOPUS. He is currently working on a research project funded by the Madhya Pradesh Council of Science and Technology (MPCST). Dr. Sharma has received several awards for his research, including the Young Research Scholar award and various awards for best oral and poster presentations at national and international conferences. His current research interest is in nanocarrier-based targeted approaches for the effective delivery of bioactives.Dr. Balak Das Kurmi is working as Associate Professor of Pharmaceutics at ISF college of Pharmacy, Moga, Punjab, INDIA. Previously he was associated at Department of Pharmacy, School of Studies of Natural Resources, Guru Ghasidas Vishwavidyalaya (A-Central University) Bilaspur (C.G.) as a DST-SERB Research fellow and CSIR-Ph.D. Fellow. He has completed B. Pharm and M. Pharm from the Department of Pharmaceutical Sciences, Dr Hari Singh Gour Central University, Sagar, M.P., India. He was awarded DST-SERB/CSIR/ICMR- Fellowship and International Travel Grant from CSIR-New Delhi. He is working on two ICMR Adhoc research Project grants more than 45 lakhs as Co-PI of project. He has expertise in various Novel Drug Delivery Systems such as Liposomes, Nanoparticles, Micelles and Dendrimers.Dr. Satish Shilpi is currently working in School of Pharmaceutical & Population Health Informatics, DIT University, Dehradun, Uttrakhand. He has completed his bachelor, master and doctorate degree in pharmacy from the Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, MP, India. He has also worked as Associate Professor and Research Coordinator in AIP, Amity University Madhya Pradesh, Gwalior in year 2022. Dr. Satish has contributed significantly to research on novel and target drug delivery especially nano and microparticles. His research interest in targeted drug delivery to MDR advanced cancer like Triple Negative Breast Cancer, Solid tumor, Lungs and Liver cancer.Dr. Swarnakar is a seasoned professional with over 15 years of experience in oral and parenteral drug product development. He currently holds the position of North America Application Lab Manager at BASF Corporation, USA. Dr. Swarnakar earned his Ph.D. in Pharmaceutical Science from the National Institute of Pharmaceutical Research and Education in Mohali, India.Before joining BASF, Dr. Swarnakar served as a Senior Scientist at TesoRx Pharma, USA. He has also held Post-Doctoral positions at the University of Connecticut, the University of Cincinnati, and Western University of Health Science, where he worked on the development of sustained release, controlled release, and enabled drug products. Dr. Swarnakar is a co-inventor of 10 patents and has authored over 30 publications. His research interests include enhancing the safety and efficacy of difficult-to-deliver drugs, formulation development for bioavailability enhancement, melt extrusion process development for pharmaceutical manufacturing, and continuous manufacturing of lipid-based drug products.Dr. Awesh K. Yadav has received his B.Pharm, M.Pharm, and PhD from Dr. Hari Singh Gour University Sagar (MP). He is currently working as Assistant Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research Raebareli, India. He has more than 15 years of teaching and industrial experience in various institutes and industries. He has written dozens of quality research publications in journals of national and international repute. He has also published four books and seven book chapters. He has been awarded the best citation award for his publication in the International Journal of Pharmaceutics in 2005. Dr. Yadav’s current research interest includes targeted and controlled novel drug delivery systems for the delivery of various bioactives such as anticancer drugs, anti-Alzheimer's drugs, anti-Parkinson drugs, anti-malarial drugs, sun-screening agents, etc.

• 1. Glioblastoma: Overview of the pathogenesis, clinical features, and diagnosis2. The challenges of brain tumour therapeutics, the future of brain tumour nanotherapeutics3. Role of Various Therapeutic Targets for in treatment of Glioblastoma4. Nanocarrier-Mediated Approaches and Conventional Therapies for Treatment Glioblastoma5. siRNA and miRNA-based strategies for management of Glioblastoma6. Lipid based nanocarrier(s) as Delivery Vehicles for Brain Tumour Therapy7. Polymeric Nanoparticulate Carrier for Brain Tumour Therapy8. Convection-Enhanced Delivery for Treatment of Glioblastoma9. Herbal approaches for treatment of glioblastoma10. Nanomedicine based photodynamic therapy for glioblastoma11. Thermoresponsive nanocarrier(s) based therapy for glioblastoma12. Peptide anchored nanocarrier(s) therapy for glioblastoma13. Theranostic applications of lipid-polymer based nanocarrier(s) for treatment of glioblastoma14. Targeting strategies in Gene Therapy for Glioblastoma15. Nanocarrier-based combination therapy for the treatment of glioblastoma16. Dendrimer assisted nanotechnological ways for glioblastoma drug delivery17. Inorganic/metallic nanoparticles in the treatment of glioblastoma18. Graphene Quantum Dots based Therapy for Glioblastoma